The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
The role of kinetic context in apparent biased agonism at GPCRs
Abstract
Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects. This mechanism is usually inferred from pharmacological data with the assumption that the confounding influences of observational (that is, assay dependent) and system (that is, cell background dependent) bias are excluded by experimental design and analysis. Here we reveal that ‘kinetic context’, as determined by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D 2 receptor and can even lead to reversals in the direction of bias. We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scikit-learn: Machine Learning in Python
Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Müller, A., Nothman, J., Louppe, G., et al. (2012) · arXiv · doi:10.48550/arxiv.1201.0490 · Cited by 71,016
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Abdi, H., & Williams, L. J. (2010) · WIREs Computational Statistics · doi:10.1002/wics.101 · Cited by 11,104
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
A Genome-Wide Association Search for Type 2 Diabetes Genes in African Americans
Palmer, N., McDonough, C. W., Hicks, P. J., Roh, B. H., Wing, M. R., An, S. S., Hester, J. M., Cooke, J. N., Bostrom, M. A., Rudock, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029202 · Cited by 1,619
Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis
Akinc, A., Thomas, M., Klibanov, A. M., & Langer, R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.696 · Cited by 1,337
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
Self-citationOperational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Conformational biosensors reveal GPCR signalling from endosomes
Irannejad, R., Tomshine, J. C., Tomshine, J. R., Chevalier, M., Mahoney, J. P., Steyaert, J., Rasmussen, S. G. F., Sunahara, R. K., El-Samad, H., Huang, B., et al. (2013) · Nature · doi:10.1038/nature12000 · Cited by 819
β-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the β2 Adrenergic Receptor
Shenoy, S. K., Drake, M. T., Nelson, C. D., Houtz, D. A., Xiao, K., Madabushi, S., Reiter, E., Premont, R. T., Lichtarge, O., & Lefkowitz, R. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506576200 · Cited by 759
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740
Self-citationBiased Signaling Pathways in β 2 -Adrenergic Receptor Characterized by 19 F-NMR
Liu, J. J., Horst, R., Katritch, V., Stevens, R. C., & Wüthrich, K. (2012) · Science · doi:10.1126/science.1215802 · Cited by 697
Structural Features for Functional Selectivity at Serotonin Receptors
Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X.-P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., et al. (2013) · Science · doi:10.1126/science.1232808 · Cited by 664
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., & Lefkowitz, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707936104 · Cited by 597
Sustained cyclic AMP production by parathyroid hormone receptor endocytosis
Ferrandon, S., Feinstein, T. N., Castro, M., Wang, B., Bouley, R., Potts, J. T., Gardella, T. J., & Vilardaga, J.-P. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.206 · Cited by 572
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 553
Therapeutic potential of β-arrestin- and G protein-biased agonists
Whalen, E. J., Rajagopal, S., & Lefkowitz, R. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.004 · Cited by 536
Ahn, S., Shenoy, S. K., Wei, H., & Lefkowitz, R. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405878200 · Cited by 508
A Simple Method for Quantifying Functional Selectivity and Agonist Bias
Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200111m · Cited by 484
Self-citationThe kinetics of competitive radioligand binding predicted by the law of mass action.
Motulsky, H. J., & Mahan, L. C. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15016-5 · Cited by 414
Quantifying Ligand Bias at Seven-Transmembrane Receptors
Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., DeWire, S. M., Violin, J. D., & Lefkowitz, R. J. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072801 · Cited by 388
Endosomes: A legitimate platform for the signaling train
Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., & Bunnett, N. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906541106 · Cited by 373
Allen, J., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S. M., Yadav, P. N., Huang, X., Feng, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104807108 · Cited by 364
Self-citationBiased ligands at G-protein-coupled receptors: promise and progress
Violin, J. D., Crombie, A. L., Soergel, D. G., & Lark, M. W. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.007 · Cited by 363
Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803522105 · Cited by 320
Galandrin, S., & Bouvier, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026716 · Cited by 292
Hill, A. V. (1909) · The Journal of Physiology · doi:10.1113/jphysiol.1909.sp001344 · Cited by 287
McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., Dewey, W. L., Bailey, C. P., Rosethorne, E. M., Charlton, S. J., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066613 · Cited by 262
Self-citationβ-Arrestin-biased Agonism at the β2-Adrenergic Receptor
Drake, M. T., Violin, J. D., Whalen, E. J., Wisler, J. W., Shenoy, S. K., & Lefkowitz, R. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708118200 · Cited by 254
Multiple ligand-specific conformations of the β2-adrenergic receptor
Kahsai, A. W., Xiao, K., Rajagopal, S., Ahn, S., Shukla, A. K., Sun, J., Oas, T. G., & Lefkowitz, R. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.634 · Cited by 254
van der Westhuizen, E. T., Breton, B., Christopoulos, A., & Bouvier, M. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.088880 · Cited by 225
Self-citationWarne, T., Edwards, P. C., Leslie, A. G. W., & Tate, C. G. (2012) · Structure · doi:10.1016/j.str.2012.03.014 · Cited by 220
Endosomal generation of cAMP in GPCR signaling
Vilardaga, J., Jean‐Alphonse, F., & Gardella, T. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1611 · Cited by 219
Chen, X., Pitis, P. M., Liu, G., Yuan, C. C.-K., Gotchev, D. B., Cowan, C. L., Rominger, D. H., Koblish, M., DeWire, S. M., Crombie, A. L., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4010829 · Cited by 218
Deciphering biased-agonism complexity reveals a new active AT1 receptor entity
Saulière, A., Bellot, M., Paris, H., Denis, C., Finana, F., Hansen, J. T., Altié, M.-F., Séguélas, M., Pathak, A., Hansen, J. L., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.961 · Cited by 212
Rahmeh, R., Damian, M., Cottet, M., Orcel, H., Mendre, C., Durroux, T., Sharma, K. S., Durand, G., Pucci, B., Trinquet, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201093109 · Cited by 203
Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 202
Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., & Laszlovszky, I. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.11.041 · Cited by 198
Guo, D. M., Mulder‐Krieger, T., IJzerman, A. P., & Heitman, L. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01897.x · Cited by 184
Griffin, M. T., Figueroa, K. W., Liller, S., & Ehlert, F. J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120857 · Cited by 123
Sykes, D. A., Dowling, M. R., & Charlton, S. J. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.054452 · Cited by 116
Self-citationElusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays
Charlton, S. J., & Vauquelin, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00863.x · Cited by 111
Self-citationLahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R. A., Carlsson, A., & Tamminga, C. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00030-9 · Cited by 104
Morphine-like Opiates Selectively Antagonize Receptor-Arrestin Interactions
Molinari, P., Vezzi, V., Sbraccia, M., Grò, M. C., Riitano, D., Ambrosio, C., Casella, I., & Costa, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059410 · Cited by 104
Shonberg, J., Lopez, L., Scammells, P. J., Christopoulos, A., Capuano, B., & Lane, J. R. (2014) · Medicinal Research Reviews · doi:10.1002/med.21318 · Cited by 101
Self-citationStallaert, W., Dorn, J. F., van der Westhuizen, E. T., Audet, M., & Bouvier, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029420 · Cited by 98
Gazi, L., Nickolls, S. A., & Strange, P. G. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705116 · Cited by 91
A Structure–Activity Analysis of Biased Agonism at the Dopamine D2 Receptor
Shonberg, J., Herenbrink, C. K., López, L., Christopoulos, A., Scammells, P. J., Capuano, B., & Lane, J. R. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401318w · Cited by 91
Self-citationProlonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias
Andreassen, K. V., Hjuler, S. T., Furness, S. G., Sexton, P. M., Christopoulos, A., Nosjean, O., Karsdal, M. A., & Henriksen, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092042 · Cited by 89
Self-citationHistidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor
Tschammer, N., Bollinger, S., Kenakin, T., & Gmeiner, P. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068106 · Cited by 77
Functionally Selective Dopamine D 2 , D 3 Receptor Partial Agonists
Möller, D., Kling, R. C., Skultety, M., Leuner, K., Hübner, H., & Gmeiner, P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5004039 · Cited by 77
The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors.
Kilpatrick, G. J., Tayar, N. E., Waterbeemd, H. V. D., Jenner, P. G., Testa, B., & MARSDEN, C. D. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10358-1 · Cited by 73
Sykes, D. A., Riddy, D., Stamp, C., Bradley, M. E., McGuiness, N., Sattikar, A., Guerini, D., Rodrigues, I., Glänzel, A., Dowling, M. R., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12620 · Cited by 72
Self-citationEmerging drugs for schizophrenia
Agid, O., Kapur, S., & Remington, G. J. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.479 · Cited by 71
Szabó, M., Herenbrink, C. K., Christopoulos, A., Lane, J. R., & Capuano, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500457x · Cited by 70
Self-citationLane, J. R., Powney, B., Wise, A., Rees, S. D., & Milligan, G. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032722 · Cited by 67
Self-citationVilums, M., Zweemer, A. J. M., Yu, Z., de Vries, H., Hillger, J. M., Wapenaar, H., Bollen, I. A. E., Barmare, F., Gross, R. S., Clemens, J. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011737 · Cited by 65
Sibley, D. R., Mahan, L. C., & Creese, I. (1983) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14291-0 · Cited by 64
Unett, D. J., Gatlin, J., Anthony, T. L., Buzard, D. J., Chang, S., Chen, C., Xiaohua, C., Dang, H. T., Frazer, J. M., Le, M. K., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.207670 · Cited by 56
Nijmeijer, S., Vischer, H. F., Rosethorne, E. M., Charlton, S. J., & Leurs, R. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080911 · Cited by 51
Self-citationPardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
Sampaio, C., Bronzova, J., Hauser, R. A., Lang, A. E., Rascol, O., Witte, S., Theeuwes, A., & Groups, F. T. R. S. (2011) · Movement Disorders · doi:10.1002/mds.23590 · Cited by 46
Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release
Carboni, L., Negri, M., Michielin, F., Bertani, S., Fratte, S. D., Oliosi, B., & Cavanni, P. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000824 · Cited by 24
A Critical Survey of Receptor Theories of Drug Action
Mackay, D. (1977) · Springer eBooks · doi:10.1007/978-3-642-66537-0_6 · Cited by 21
Nijmeijer, S., Vischer, H. F., Rosethorne, E. M., Charlton, S. J., & Leurs, R. (2012) · Cited by 12
Self-citationA Multiplexed Fluorescent Calcium and NFAT Reporter Gene Assay to Identify GPCR Agonists
Sheth, H. J. (2013) · Current Chemical Genomics · doi:10.2174/2213988501307010001 · Cited by 10
Research works printed but not linked: 1
- Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193–203 (2012). · DOI · Paper page
Cited by
How Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336
Self-citationCommunity guidelines for GPCR ligand bias: IUPHAR review 32
Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., Bouvier, M., Hill, S. J., Kostenis, E., Martemyanov, K. A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15811 · Cited by 232
Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., & Charlton, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00716-z · Cited by 218
Self-citationAllostery and biased agonism at class B G protein-coupled receptors
Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00049 · Cited by 112
Self-citation
Metadata
- Authors
- Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., Javitch, J. A., Christopoulos, A., & Lane, J. R.
- Venue
- Nature Communications
- Published
- 2016-02-24
- Volume
- 7
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 328
- References
- 65
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
